Follicular Lymphoma Treatment Market Growth – at a CAGR of 7.6% During Forecast Period 2020-2028

Growing prevalence of follicular lymphoma worldwide and rising need for improved and more advanced treatment for the condition are among the key factors driving the global market revenue growth.

Growing prevalence of follicular lymphoma worldwide and rising need for improved and more advanced treatment for the condition are among the key factors driving the global market revenue growth

Emergen Research has published its latest report titled “Follicular Lymphoma Treatment Market, By Treatment (Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents, Nucleoside Analogues, Anthracycline Derivatives, Others), By Route of Administration (Oral, Parenteral, Others), By End-use (Hospitals & Clinics, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Others), and By Region Forecast to 2028”

According to Emergen Research, the global follicular lymphoma treatment market size was USD 2.23 billion in 2020 and is expected to reach USD 4.01 billion in 2028 and register a revenue CAGR of 7.6% during the forecast period, 2021-2028.

Click Here to Access Free sample PDF Copy of the Report@ https://www.emergenresearch.com/request-sample/51

Market Dynamics:

Key factors contributing to the global follicular lymphoma treatment market revenue growth are growing prevalence of follicular lymphoma across the globe, rising occurrence of blood disorders, rising awareness of blood cancer worldwide, and increasing research & development activities for newer and more advanced drugs and treatment methods for the disease. Rising awareness of early diagnosis and treatment of various blood cancers, increasing use of monoclonal antibodies in follicular lymphoma treatment, rise in government initiatives towards advanced cancer management, and increasing regulatory approvals for new and promising pipeline drugs are among the other major factors expected to boost the global market revenue growth over the forecast period. For instance, the U.S. FDA approved the Tazemetostat drug for treatment of relapsed or refractory follicular lymphoma in adults in June 2020.

Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL), one of the most common blood cancer types. This type of cancer is slow-growing and affects the lymphatic system of the body, leading to rapid and abnormal growth of B lymphocytes in the blood. Common symptoms of the disease include fatigue, weight loss, night sweats, shortness of breath, and enlargement of the lymph node in various body parts such as the groin, abdomen, and neck. Follicular lymphoma is the second most prevalent sub-type of non-Hodgkin lymphoma in the world. As estimated by the National Cancer Institute, NIH, over 72,000 people in the U.S. were diagnosed with several forms of NHL in 2017. Some of the most common treatment methods for follicular lymphoma are chemotherapy, radiation therapy, targeted therapy, and stem cell transplantation. Advances in chemotherapy and radiation techniques for more effective treatment of follicular lymphoma are expected to further drive the global follicular lymphoma treatment market revenue growth.

COVID-19 Impact Analysis:

  • Social distancing and restrictions severely disrupted businesses and operations
  • Lockdowns caused disruptions in transportation and logistics
  • Impacted manufacturing activities and mining operations globally
  • Took a toll on economy of various countries
  • Caused sudden and drastic downturn in economic activity
  • Disrupted agriculture, fisheries, dairy, and other sectors
  • Caused loss of employment and financial crisis
  • Supply impacts were further compounded owing to reduced disposable income
  • Emergence of variants continue to cause concerns and impact normal routines

Targeted Therapy Segment Accounted for Largest Revenue Share in 2020:

Based on treatment, the global follicular lymphoma treatment market is segmented into Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents, Nucleoside Analogues, Anthracycline Derivatives, and Others. The targeted therapy segment dominated other segments in terms of revenue share in the global market in 2020. Rising prevalence of follicular lymphoma worldwide, increasing awareness of early detection and treatment of blood cancer, growing need for more advanced diagnostic and treatment methods for follicular lymphoma, and growing preference for targeted therapy for follicular lymphoma treatment are major factors driving revenue growth of this segment.

Looking for Discount [Click on the link] @ https://www.emergenresearch.com/request-discount/51

Hospitals & Clinics Segment to Account for Fastest Revenue CAGR:

Based on end-use, the global follicular lymphoma treatment market is segmented into Hospitals & Clinics, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, and Others. The hospitals segment is expected to register the fastest revenue growth rate in the global market over the forecast period. Key factors supporting revenue growth of this segment are rising prevalence of blood cancer, increasing cases of follicular lymphoma, and rapid adoption of highly advanced diagnostic and treatment methods in hospitals.

North America Accounted for Largest Revenue Share in 2020:

Among regional markets, the North America follicular lymphoma treatment market led in terms of largest revenue share in the global market in 2020. Rising prevalence of non-Hodgkin lymphoma, increasing cases of follicular lymphoma, introduction of technologically advanced follicular lymphoma diagnostic and treatment methods, and presence of advanced healthcare infrastructure and key market players in the region, including Bristol Myers Squibb and Company, AbbVie, Inc., and Johnson and Johnson Services, Inc., are major factors contributing to the regional market revenue growth.

Major Companies in the Global Follicular Lymphoma Treatment Market Include:

  • AbbVie, Inc.
  • Celgene Corporation
  • Bayer AG
  • Bristol Myers Squibb and Company
  • Epizyme Inc.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson and Johnson Services, Inc.
  • Merck & Co. Inc.
  • Novartis AG

Have a look at Report Description and Table of Contents of Market Report@ https://www.emergenresearch.com/industry-report/follicular-lymphoma-treatment-market

For the purpose of this report, Emergen Research has segmented the global follicular lymphoma treatment market on the basis of treatment, route of administration, end-use, and region:

Treatment Outlook (Revenue, USD Billion; 2018-2028)

  • Monoclonal Antibodies
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Stem Cell Transplant
  • Alkylating Agents
  • Nucleoside Analogues
  • Anthracycline Derivatives
  • Others

Route of Administration Outlook (Revenue, USD Billion; 2018-2028)

  • Oral
  • Parenteral
  • Others

End-use Outlook (Revenue, USD Billion; 2018-2028)

  • Hospitals
  • Oncology Centers
  • Ambulatory Care Centers
  • Academic Research Institutes
  • Others

Region Outlook (Revenue, USD Billion; 2018-2028)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • BENELUX
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Turkey
    • Rest of Middle East & Africa

Explore Reports offered by Emergen Research:

The global micro mobility market size is expected to reach USD 290.39 Billion by 2028, at a CAGR of 18.8% during the forecast period. Market revenue growth is primarily driven by increasing traffic congestion and longer urban commutes.

The global vehicle-to-everything (V2X) market size was USD 677.9 Million in 2020 and is projected to reach a market size of USD 11.27 Billion in 2028 and register a CAGR of 41.8% during the forecast period. Rising incidence of road accidents is a key factor driving demand for vehicle-to-everything communications.

The global solar vehicle market size was USD 290.7 Million in 2020, which is expected to reach USD 2,899.7 Million in 2027 and register a robust double-digit CAGR of 38.9% during the forecast period. Market growth is primarily driven by rising interest in renewable and sustainable energy resources and systems.

The global driving simulator market size reached USD 4.56 Billion in 2020 and is expected to register a steady CAGR of 3.3% during the forecast period. Rising focus and growing investment in research and development activities, technological advancements, increasing adoption of driving simulation technologies by car manufacturing companies, and rapid advancements in autonomous vehicles are some key factors boosting revenue growth of the global driving simulator market.

The global automotive airbag silicone market size reached USD 237.5 Million in 2020 and is expected to register a CAGR of 15.4% during the forecast period. Growing number of silicone-coated airbags per vehicle is a key factor expected to drive global automotive airbag silicone market growth during the forecast period.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Read Our Press release@ https://www.emergenresearch.com/press-release/global-follicular-lymphoma-treatment-market